Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

FGF23 induces left ventricular hypertrophy.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M.

J Clin Invest. 2011 Nov;121(11):4393-408. doi: 10.1172/JCI46122. Epub 2011 Oct 10.

2.

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.

Leifheit-Nestler M, Große Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, Klintschar M, Becker JU, Erbersdobler A, Aufricht C, Seeman T, Fischer DC, Faul C, Haffner D.

Nephrol Dial Transplant. 2015 Dec 17. pii: gfv421. [Epub ahead of print]

PMID:
26681731
3.

Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.

Hsu HJ, Wu MS.

Am J Med Sci. 2009 Feb;337(2):116-22. doi: 10.1097/MAJ.0b013e3181815498.

PMID:
19214027
4.

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.

Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstädt H, Wolf M, Faul C, Brand M.

Nephrol Dial Transplant. 2014 Nov;29(11):2028-35. doi: 10.1093/ndt/gfu190. Epub 2014 May 29.

5.

Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.

Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M.

Atherosclerosis. 2013 Nov;231(1):114-9. doi: 10.1016/j.atherosclerosis.2013.09.002. Epub 2013 Sep 13.

6.

The role of fibroblast growth factor-23 in cardiorenal syndrome.

Kovesdy CP, Quarles LD.

Nephron Clin Pract. 2013;123(3-4):194-201. doi: 10.1159/000353593. Epub 2013 Aug 6. Review.

7.

Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.

Yang K, Wang C, Nie L, Zhao X, Gu J, Guan X, Wang S, Xiao T, Xu X, He T, Xia X, Wang J, Zhao J.

J Am Soc Nephrol. 2015 Oct;26(10):2434-46. doi: 10.1681/ASN.2014060543. Epub 2015 Mar 24.

PMID:
25804281
8.

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald LF, Stubbs JR, Wacker MJ.

Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E863-73. doi: 10.1152/ajpendo.00596.2012. Epub 2013 Feb 26.

9.

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C.

Cell Metab. 2015 Dec 1;22(6):1020-32. doi: 10.1016/j.cmet.2015.09.002. Epub 2015 Oct 1.

PMID:
26437603
10.

Fibroblast growth factor-23 and cardiac structure and function.

Agarwal I, Ide N, Ix JH, Kestenbaum B, Lanske B, Schiller NB, Whooley MA, Mukamal KJ.

J Am Heart Assoc. 2014 Feb 13;3(1):e000584. doi: 10.1161/JAHA.113.000584.

11.

Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.

Xie J, Yoon J, An SW, Kuro-o M, Huang CL.

J Am Soc Nephrol. 2015 May;26(5):1150-60. doi: 10.1681/ASN.2014040325. Epub 2014 Dec 4.

12.

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE.

Atherosclerosis. 2009 Dec;207(2):546-51. doi: 10.1016/j.atherosclerosis.2009.05.013. Epub 2009 May 21.

PMID:
19524924
13.

Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.

Koizumi M, Komaba H, Fukagawa M.

Contrib Nephrol. 2013;180:110-23. doi: 10.1159/000346791. Epub 2013 May 3. Review.

PMID:
23652554
14.

S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.

Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, Hofmann Bowman MA.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1399-411. doi: 10.1161/ATVBAHA.114.303508. Epub 2014 May 22.

16.

Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Seifert ME, de Las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.

Am J Nephrol. 2014;39(5):392-9. doi: 10.1159/000362251. Epub 2014 May 6.

17.

[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].

Komaba H.

Clin Calcium. 2010 Jul;20(7):1028-36. doi: CliCa100710281036. Review. Japanese.

PMID:
20585181
18.

Fibroblast growth factor 23 and the heart.

Faul C.

Curr Opin Nephrol Hypertens. 2012 Jul;21(4):369-75. doi: 10.1097/MNH.0b013e32835422c4. Review.

PMID:
22531163
19.

FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.

Silswal N, Touchberry CD, Daniel DR, McCarthy DL, Zhang S, Andresen J, Stubbs JR, Wacker MJ.

Am J Physiol Endocrinol Metab. 2014 Sep 1;307(5):E426-36. doi: 10.1152/ajpendo.00264.2014. Epub 2014 Jul 22.

20.

Regulation of fibroblast growth factor-23 signaling by klotho.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M.

J Biol Chem. 2006 Mar 10;281(10):6120-3. Epub 2006 Jan 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk